Comprehensive genomic profiling of advanced stage endometrioid endometrial adenocarcinomas (EEAC) reveals differences associated with <em>CTNNB1</em> mutation status and a high frequency of clinically relevant genomic alterations

Elvin, Julia

152
Comprehensive genomic profiling of advanced stage endometrioid endometrial adenocarcinomas (EEAC) reveals differences associated with CTNNB1 mutation status and a high frequency of clinically relevant genomic alterations

Sunday, March 29, 2015: 3:05 PM

Salon C-D (Hilton Chicago)

J. A. Elvin¹, K. Wang¹, S. M. Ali¹, J. Chmielecki¹, P. J. Stephens¹, O. Dorigo² and J. S. Ross^1,3
¹Foundation Medicine, Inc., Cambridge, MA, ²Stanford Hospital and Clinics, Stanford, CA, ³Albany Medical College, Albany, NY

2015 Annual Meeting on Women's Cancer®

March 26 - 31, 2015

Navigation

152
Comprehensive genomic profiling of advanced stage endometrioid endometrial adenocarcinomas (EEAC) reveals differences associated with CTNNB1 mutation status and a high frequency of clinically relevant genomic alterations

152 Comprehensive genomic profiling of advanced stage endometrioid endometrial adenocarcinomas (EEAC) reveals differences associated with CTNNB1 mutation status and a high frequency of clinically relevant genomic alterations

152
Comprehensive genomic profiling of advanced stage endometrioid endometrial adenocarcinomas (EEAC) reveals differences associated with CTNNB1 mutation status and a high frequency of clinically relevant genomic alterations